APGE Stock Analysis: Apogee Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.993m USD | 12M Return: 240.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 265M
Warnings
Tailwinds
Seasonality 3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Apogee Therapeutics, Inc. (NASDAQ: APGE) is a U.S.-based clinical-stage biotechnology company founded in 2022 and headquartered in Waltham, Massachusetts. It focuses on developing novel biologics, primarily monoclonal antibodies, for inflammatory and immunology indications including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its lead candidate, Zumilokibart (APG777), is a subcutaneous extended half-life monoclonal antibody currently in Phase 2 trials for atopic dermatitis and Phase 1 trials for asthma and eosinophilic esophagitis, supported by earlier-stage programs such as APG279, APG273, and APG808.
As a clinical-stage biotech with no approved products, Apogee is pre-commercial and typically relies on equity financing and capital markets rather than product revenue to fund its research and development pipeline. Biologics and monoclonal antibody therapies targeting Type 2 inflammatory pathways represent a major and growing segment of the immunology drug market, though candidates must still navigate multi-year clinical trials and regulatory review before generating revenue.
- APG777 Phase 2 atopic dermatitis data readout
- Competition intensifies from Dupixent and Lillys Ebglyss
- Cash runway supports pipeline advancement through key catalysts
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 8.85 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -234.5m > Net Income -274.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 32.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.7m) vs 12m ago 19.71% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.80 (Total Current Assets 1.07b - Total Current Liabilities 33.0m) / Total Assets 1.29b |
| B: -0.49 (Retained Earnings -635.9m / Total Assets 1.29b) |
| C: -0.27 (EBIT TTM -274.3m / Avg Total Assets 1.00b) |
| D: 33.17 (Book Value of Equity 1.26b / Total Liabilities 37.9m) |
| Altman-Z'' = 36.67 = AAA |
As of July 08, 2026, the stock is trading at USD 133.54 with a total of 1,054,061 shares traded. Over the past week, the price has changed by +0.70%, over one month by +60.87%, over three months by +60.35% and over the past year by +240.32%.
Current recommended Stop Loss: 128.60 (which is 3.7% or 1.2 ATR below the current price).
Apogee Therapeutics, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy APGE.
- StrongBuy: 9
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 130.5 | -2.3% |
P/B = 7.9489
Revenue TTM = 0.0 USD
EBIT TTM = -274.3m USD
EBITDA TTM = -272.7m USD
Long Term Debt = 4.91m USD (estimated: total debt 8.05m - short term 3.14m)
Short Term Debt = 3.14m USD (from shortTermDebt, last quarter)
Debt = 8.05m USD (from shortLongTermDebtTotal, last quarter) (leases 8.05m already included)
Net Debt = -1.05b USD (calculated: Debt 8.05m - CCE 1.06b)
Enterprise Value = 8.94b USD (9.99b + Debt 8.05m - CCE 1.06b)
Interest Coverage Ratio = unknown (Ebit TTM -274.3m / Interest Expense TTM 0.0)
EV/FCF = -37.99x (Enterprise Value 8.94b / FCF TTM -235.4m)
FCF Yield = -2.63% (FCF TTM -235.4m / Enterprise Value 8.94b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 808k) / Revenue TTM)
Tobins Q-Ratio = 6.91 (Enterprise Value 8.94b / Total Assets 1.29b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.05m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -216.7m (EBIT -274.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 32.59 (Total Current Assets 1.07b / Total Current Liabilities 33.0m)
Debt / Equity = 0.01 (Debt 8.05m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 3.86 (negative EBITDA) (Net Debt -1.05b / EBITDA -272.7m)
Debt / FCF = 4.47 (negative FCF - burning cash) (Net Debt -1.05b / FCF TTM -235.4m)
Total Stockholder Equity = 841.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.35% (Net Income -274.6m / Total Assets 1.29b)
RoE = -32.64% (Net Income TTM -274.6m / Total Stockholder Equity 841.4m)
RoCE = -32.42% (EBIT -274.3m / Capital Employed (Equity 841.4m + L.T.Debt 4.91m))
RoIC = -17.15% (negative operating profit) (NOPAT -216.7m / Invested Capital 1.26b)
WACC = 10.01% (E(9.99b)/V(10.0b) * Re(10.02%) + D(8.05m)/V(10.0b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 15.22%
[DCF] Fair Price = unknown (Cash Flow -235.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.27 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.96 | Chg30d=+13.12% | Revisions=+80% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-1.16 | Chg30d=+1.05% | Revisions=+53% | Analysts=11
EPS current Year (2026-12-31): EPS=-4.41 | Chg30d=+3.71% | Revisions=+69% | GrowthEPS=-4.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.19 | Chg30d=+1.49% | Revisions=+35% | GrowthEPS=-17.6% | GrowthRev=+37.5%
[Analyst] Revisions Ratio: +69% (up=44, down=7)